Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MIRM
MIRM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MIRM News
Investors Must Maintain Emotional Neutrality
Jun 29 2026
NASDAQ.COM
Mirum and Incyte Report Positive Results for FOP Study
Jun 17 2026
NASDAQ.COM
Mirum and Incyte Report Positive Phase 2 Data for Zilurgisertib
Jun 15 2026
seekingalpha
Mirum and Incyte Announce Positive Phase 2 Results for Zilurgisertib
Jun 15 2026
NASDAQ.COM
Mirum and Incyte Announce New Progress in FOP Treatment
Jun 14 2026
Yahoo Finance
Mirum and Incyte Announce FOP Study Results
Jun 14 2026
Newsfilter
Latest Rating Changes on Wall Street
Jun 02 2026
CNBC
Mirum Pharmaceuticals Unveils New Liver Disease Treatment Data
May 30 2026
Newsfilter
Mirum Pharmaceuticals Completes $600M Convertible Note Offering
May 13 2026
seekingalpha
Mirum Pharmaceuticals Prices $600 Million Convertible Notes Offering
May 13 2026
Newsfilter
Mirum Pharmaceuticals Q1 2026 Earnings Call Insights
May 07 2026
seekingalpha
Mirum's Drug Trial Shows Significant Itch Relief in Liver Disease
May 04 2026
stocktwits
Mirum Pharmaceuticals' VISTAS Study Achieves Success
May 04 2026
NASDAQ.COM
Mirum Pharmaceuticals to Report VISTAS Trial Results Today
May 04 2026
NASDAQ.COM
Mirum Pharmaceuticals to Host Investor Call on VISTAS Study Results
May 03 2026
Newsfilter
Mirum Pharmaceuticals' AZURE-1 Study Achieves Key Endpoint
Apr 27 2026
NASDAQ.COM
Show More News
